Biotech News
Related news
MNKDMannKind2026-07-28 20:01 EST
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
MNKDMannKind2026-11-05 21:01 EST
MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update
CVRXCVRx2026-10-22 20:30 EST
CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026
MLYSMineralys Therapeutics2026-10-28 20:05 EST
Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
ALTAltimmune2026-11-05 13:00 EST
Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
LXRXLexicon Pharmaceuticals2026-10-29 12:30 EST
Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
RYTMRhythm Pharmaceuticals2026-10-21 12:00 EST
Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
CVRXCVRx2026-07-23 20:30 EST
CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026
MISTMilestone Pharmaceuticals Inc.2026-11-03 13:00 EST
Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026
SENSSenseonics2026-10-21 12:00 EST
Senseonics Holdings, Inc. Schedules Third Quarter 2026 Earnings Release and Conference Call for November 9, 2026 at 4:30 P.M. Eastern Time
MannKind
Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid...
Recent company news
MNKDMannKind2026-11-05 21:01 EST
MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update
MNKDMannKind2026-10-29 20:01 EST
MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026
MNKDMannKind2026-10-14 20:01 EST
MannKind to Participate in the Chardan Healthcare Conference
MNKDMannKind2026-10-10 00:00 EST
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
MNKDMannKind2026-09-09 10:30 EST
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
Stock data
- Close
- 3.76 USD
- Market cap
- 1.06B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States